Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 1 , Pages 15-33 , March 2006

Strengths and weaknesses of in vitro assays for estrogenic and androgenic activity

References 

  1. Soto AM, Justicia H, Wray JW, Sonnenschein C. p-Nonyl-phenol: an estrogenic xenobiotic released from ‘modified’ polystyrene. Environmental Health Perspectives. 1991;92:167–173
  2. Soto AM, Chung KL, Sonnenschein C. The pesticides endosulfan, toxaphene, and dieldrin have estrogenic effects on human estrogen sensitive cells. Environmental Health Perspectives. 1994;102:380–383
  3. Soto AM, Sonnenschein C, Chung KL, et al. The E-SCREEN assay as a tool to identify estrogens: an update on estrogenic environmental pollutants. Environmental Health Perspectives. 1995;103:113–122
  4. Soto AM, Michaelson CL, Prechtl NV, et al. Assay to measure estrogen and androgen agonists and antagonists. In:  del Mazo J editors. In Vitro Germ Cell Developmental Toxicology: From Science to Social and Industrial Demand. New York, NY: Plenum Press Publishing Co.; 1998;p. 9–28
  5. Schlumpf M, Cotton B, Conscience M, et al. In vitro and in vivo estrogenicity of UV screens. Environmental Health Perspectives. 2001;109:239–244
  6. Herbst AL, Bern HA. Developmental Effects of Diethylstilbestrol (DES) in Pregnancy. New York, NY: Thieme-Stratton; 1988;
  7. Mittendorf R. Teratogen update: carcinogenesis and teratogenesis associated with exposure to diethylstilbestrol (DES) in utero. Teratology. 1995;51:435–445
  8. Wingspread consensus statement. In:  Colborn T,  Clement C editor. Chemically Induced Alterations in Sexual and Fuctional Development: The Wildlife/Human Connection. Princeton, NJ: Princeton Scientific Publishing; 1992;p. 1–8
  9. Carlsen E, Giwercman A, Keinding N, Skakkebaek NE. Evidence for the decreasing quality of semen during the past 50 years. British Medical Journal. 1992;305:609–612
  10. Giwercman A, Carlsen E, Keiding N, Skakkebaek NE. Evidence for increasing incidence of abnormalities of the human testis: a review. Environmental Health Perspectives. 1993;101:65–71
  11. Sharpe RM, Skakkebaek NE. Are oestrogens involved in falling sperm count and disorders of the male reproductive tract?. Lancet. 1993;341:1392–1395
  12. Körner W, Bolz U, Sussmuth W, et al. Input/output balance of estrogenic active compounds in a major municipal sewage plant in Germany. Chemosphere. 2000;40:1131–1142
  13. Colborn T, vom Saal FS, Soto AM. Developmental effects of endocrine-disrupting chemicals in wildlife and humans. Environmental Health Perspectives. 1993;101:378–384
  14. Baker ME, Medlock KL, Sheehan DM. Flavonoids inhibit estrogen binding to rat alpha-fetoprotein. Proceedings of the Society for Experimental Biology and Medicine. 1998;217:317–321
  15. Sheehan DM, Young M. Diethylstilbestrol and estradiol binding to serum albumin and pregnancy plasma of rat and human. Endocrinology. 1979;104:1442–1446
  16. Kuiper GGJM, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology. 1998;139:4252–4263
  17. Dupont S, Krust A, Gansmuller A, et al. Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. Development. 2000;127:4277–4291
  18. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997;138:863–870
  19. Koehler KF, Helguero LA, Haldosen LA, et al. Reflections on the discovery and significance of estrogen receptor beta. Endocrine Reviews. 2005;26:465–478
  20. Norfleet AM, Clarke CH, Gametchu B, Watson CS. Antibodies to the estrogen receptor-alpha modulate rapid prolactin release from rat pituitary tumor cells through plasma membrane estrogen receptors. FEBS Journal. 2004;14:157–165
  21. Powell CE, Soto AM, Sonnenschein C. Identification and characterization of membrane estrogen receptor from MCF7 estrogen-target cells. The Journal of Steroid Biochemistry Molecular Biology. 2001;77:97–108
  22. Sonnenschein C, Soto AM, Michaelson CL. Human serum albumin shares the properties of estrocolyone-I, the inhibitor of the proliferation of estrogen-target cells. The Journal of Steroid Biochemistry Molecular Biology. 1996;59:147–154
  23. Powell CE, Soto AM, Michaelson CL, et al. Plasma membrane-resident albumin binding protein associated with the proliferation of MCF7 serum-sensitive cells. Steroids. 2003;68:487–496
  24. Bulayeva NN, Watson CS. Xenoestrogen-induced ERK-1 and ERK-2 activation via multiple membrane-initiated signaling pathways. Environmental Health Perspectives. 2004;112:1481–1487
  25. Watson CS, Bulayeva NN, Wozniak AL, Finnerty CC. Signaling from the membrane via membrane estrogen receptor-alpha: estrogens, xenoestrogens, and phytoestrogens. Steroids. 2005;70:364–371
  26. Desbrow C, Routledge EJ, Brighty GC, et al. Identification of estrogenic chemicals in STW effluent. 1. Chemical fractionation and in vitro biological screening. Environmental Science and Technology. 1998;32:1549–1558
  27. Soto AM, Calabro JM, Prechtl NV, et al. Androgenic and estrogenic activity in cattle feedlot effluent receiving water bodies of eastern Nebraska, USA. Environmental Health Perspectives. 2004;112:346–352
  28. Sonnenschein C, Soto AM, Fernandez MF, et al. Development of a marker of estrogenic exposure in human serum. Clinical Chemistry. 1995;41:1888–1895
  29. Soto AM, Fernandez MF, Luizzi MF, et al. Developing a marker of exposure to xenoestrogen mixtures in human serum. Environmental Health Perspectives. 1997;105:647–654
  30. Ibarluzea JM, Fernández MF, Santa-Marina L, et al. Breast cancer risk in the combined effect of environmental estrogens. Cancer Causes Control. 2004;15:591–600
  31. Hertz R. The estrogen problem—retrospect and prospect. In:  McLachlan JA editors. Estrogens in the Environment II- Influences on Development. New York, NY: Elsevier; 1985;p. 1–11
  32. Bolger R, Wiese TE, Ervin K, et al. Rapid screening of environmental chemicals for estrogen receptor binding capacity. Environmental Health Perspectives. 1998;106:551–557
  33. Soto AM, Sonnenschein C. Mechanism of estrogen action on cellular proliferation: evidence for indirect and negative control on cloned breast tumor cells. Biochemical and Biophysical Research Communications. 1984;122:1097–1103
  34. Reiner GCA, Katzenellenbogen BS, Bindal RD, Katzenellenbogen JA. Biological activity and receptor binding of a strongly interacting estrogen in human breast cancer cells. Cancer Research. 1984;44:2302–2308
  35. Jeltsch JM, Roberts M, Scatz C, et al. Structure of the human oestrogen-responsive gene pS2. Nucleic Acids Research. 1987;15:1401–1414
  36. Soto AM, Lin T-M, Justicia H, et al. An ‘in culture’ bioassay to assess the estrogenicity of xenobiotics. In:  Colborn T,  Clement C editor. Chemically Induced Alterations in Sexual Development: The Wildlife/Human Connection. Princeton, NJ: Princeton Scientific Publishing; 1992;p. 295–309
  37. Markey CM, Michaelson CL, Veson EC, et al. The mouse uterotropic assay: a re-evaluation of its validity in assessing the estrogenicity of bisphenol A. Environmental Health Perspectives. 2001;109:55–60
  38. Newbold RR, Jefferson WN, Padilla-Banks E, et al. Cell response endpoints enhance sensitivity of the immature mouse uterotropic assay. Reproductive Toxicology. 2001;15:245–252
  39. Pugazhendhi D, Pope GS, Darbre PD. Oestrogenic activity of p-hydroxybenzoic acid (common metabolite of paraben esters) and methylparaben in human breast cancer cell lines. Journal of Applied Toxicology. 2005;24:301–309
  40. Pons M, Gagne D, Nicolas JC, Mehtali M. A new cellular model of response to estrogens: a bioluminescent test to characterize (anti) estrogen molecules. Biotechniques. 1990;9:450–459
  41. Gagne D, Balaguer P, Demirpence E, et al. Stable luciferase transfected cells for studying steroid receptor biological activity. Journal of Bioluminescence and Chemiluminescence. 1994;9:201–209
  42. Badia E, Duchesne MJ, Fournier-Bidoz S, et al. Hydroxytamoxifen induces a rapid and irreversible inactivation of an estrogenic response in an MCF-7-derived cell line. Cancer Research. 1994;54:5860–5866
  43. Oliva J, Messaoudi SE, Pellestor F, et al. Involvement of HP1alpha protein in irreversible transcriptional inactivation by antiestrogens in breast cancer cells. FEBS Letters. 2005;579:4278–4286
  44. Shiau SP, Glasebrook A, Hardikar SD, et al. Activation of the human estrogen receptor by estrogenic and antiestrogenic compounds in Saccharomyces cerevisiae: a positive selection system. Gene. 1996;179:205–210
  45. Zysk JR, Johnson B, Ozenberger BA, et al. Selective uptake of estrogenic compounds by saccharomyces cerevisiae: a mechanism for antiestrogen resistance in yeast expressing the mammalian estrogen receptor. Endocrinology. 1995;136:1323–1326
  46. Gaido KW, Leonard LS, Lovell S, et al. Evaluation of chemicals with endocrine modulating activity in a yeast-based steroid hormone receptor gene transcription assay. Toxicology and Applied Pharmacology. 1997;143:205–212
  47. Andersen HR, Andersson AM, Arnold SF, et al. Comparison of short-term estrogenicity tests for identification of hormone-disrupting chemicals. Environmental Health Perspectives. 1999;107(supplement 1):89–108
  48. Fang H, Tong W, Perkins R, et al. Quantitative comparisons of in vitro assays for estrogenic activities. Environmental Health Perspectives. 2000;108:723–729
  49. Rajapakse N, Silva E, Scholze M, Kortenkamp A. Deviation from additivity with estrogenic mixtures containing 4-nonylphenol and 4-tert-octylphenol detected in the E-SCREEN assay. Environmental Science and Technology. 2004;38:6343–6352
  50. Rasmussen TH, Nielsen F, Andersen HR, et al. Assessment of xenoestrogenic exposure by a biomarker approach: application of the E-Screen bioassay to determine estrogenic response of serum extracts. Environmental Health. 2003;2:12
  51. Dalton JT, Mukherjee A, Zhu Z, et al. Discovery of nonsteroidal androgens. Biochemical and Biophysical Research Communications. 1998;244:1–4
  52. Cook JC, Mullin LS, Frame SR, Biegel LB. Investigation of a mechanism for Leydig cell tumorigenesis by linuron in rats. Toxicology and Applied Pharmacology. 1993;119:195–204
  53. Fail PA, Pearce SW, Anderson SA, et al. Endocrine and reproductive toxicity of vinclozolin (vin) in male Long-Evans hooded rats. Fundamental and Applied Toxicology. 1995;15:293
  54. Gray LE, Ostby JS, Kelce WR. Developmental effects of an environmental antiandrogen: the fungicide vinclozolin alters sex differentiation of the male rat. Toxicology and Applied Pharmacology. 1994;129:46–52
  55. Kelce WR, Stone CR, Laws SC, et al. Persistent DDT metabolite p,p′-DDE is a potent androgen receptor antagonist. Nature. 1995;375:581–585
  56. Vinggaard AM, Nellemann C, Dalgaard M, et al. Antiandrogenic effects in vitro and in vivo of the fungicide prochloraz. Toxicological Sciences. 2002;69:344–353
  57. Kelce WR, Monosson E, Gamcsik MP, et al. Environmental hormone disruptors: evidence that vinclozolin developmental toxicity is mediated by antiandrogenic metabolites. Toxicology and Applied Pharmacology. 1994;126:276–285
  58. Vinggaard AM, Hnida C, Larsen JC. Environmental polycyclic aromatic hydrocarbons affect androgen receptor activation in vitro. Toxicology. 2000;145:159–169
  59. Saltzman AG, Hiipakka RA, Chang C, Liao S. Androgen repression of the production of a 29-kilodalton protein and its mRNA in the rat ventral prostate. The Journal of Biological Chemistry. 1987;262:432–437
  60. Paris F, Balaguer P, Térouanne B, et al. Phenylphenols, biphenols, bisphenol-A and 4-tert-octylphenol exhibit alpha and beta estrogen activities and antiandrogen activity in reporter cell lines. Molecular and Cellular Endocrinology. 2002;193:43–49
  61. Fang H, Tong W, Branham WS, et al. Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor. Chemical Research in Toxicology. 2003;16:1338–1358
  62. Horoszewicz JS, Leong SS, Kawinski E, et al. LNCaP model of human prostatic carcinoma. Cancer Research. 1983;43:1809–1818
  63. Veldscholte J, Voorhorst-Ogink MM, Bolt-de Vries J, et al. Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: high affinity for progestagenic and estrogenic steroids. Biochimica et Biophysica Acta. 1990;1052:187–194
  64. Veldscholte J, Ris-Stalpers C, Kuiper GG, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochemical and Biophysical Research Communications. 1990;173:534–540
  65. Sonnenschein C, Olea N, Pasanen ME, Soto AM. Negative controls of cell proliferation: human prostate cancer cells and androgens. Cancer Research. 1989;49:3474–3481
  66. Olea N, Sakabe K, Soto AM, Sonnenschein C. The proliferative effect of ‘anti-androgens’ on the androgen- sensitive human prostate tumor cell line LNCaP. Endocrinology. 1990;126:1457–1463
  67. Soto AM, Lin TM, Sakabe K, et al. Variants of the human prostate LNCaP cell line as a tool to study discrete components of the androgen-mediated proliferative response. Oncology Research. 1995;7:545–558
  68. Young CY, Montgomery BT, Andrews PE, et al. Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Research. 1991;51:3748–3752
  69. Montgomery BT, Young CYF, Bilhartz DL, et al. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate. 1992;21:63–73
  70. Szelei J, Jimenez J, Soto AM, et al. Androgen-induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor. Endocrinology. 1997;138:1406–1412
  71. Soto AM, Sonnenschein C. Cell proliferation of estrogen-sensitive cells: the case for negative control. Endocrine Reviews. 1987;8:44–52
  72. Maffini MV, Geck P, Powell CE, et al. Mechanism of androgen action on cell proliferation AS3 protein as a mediator of proliferative arrest in the rat prostate. Endocrinology. 2002;143:2708–2714
  73. Geck P, Maffini MV, Szelei J, et al. Androgen-induced proliferative quiescence in prostate cancer: the role of AS3 as its mediator. Proceedings of the National Academy of Sciences of the United States of America. 2000;97:10185–10190
  74. Wilson VS, Bobseine K, Lambright CR, Gray LE. A novel cell line, MDA-kb2, that stably expresses an androgen- and glucocorticoid-responsive reporter for the detection of hormone receptor agonists and antagonists. Toxicological Sciences. 2002;66:69–81
  75. Térouanne B, Tahiri B, Georget V, et al. A stable prostatic bioluminescent cell line to investigate androgen and antiandrogen effects. Molecular and Cellular Endocrinology. 2000;160:39–49
  76. Sonneveld E, Jansen JH, Riteco JAC, et al. Development of androgen- and estrogen-responsive bioassays, members of a panel of human cell line-based highly selective steroid-responsive bioassays. Toxicological Sciences. 2005;83:136–148
  77. Körner W, Vinggaard AM, Térouanne B, et al. Interlaboratory comparison of four in vitro assays for assessing androgenic and antiandrogenic activity of environmental chemicals. Environmental Health Perspectives. 2004;112:695–702
  78. Terouanne B, Tahiri B, Georget V, et al. A stable prostatic bioluminescent cell line to investigate androgen and antiandrogen effects. Molecular and Cellular Endocrinology. 2000;160:39–49
  79. EDSTAC . Endocrine Disruptor Screening and Testing Advisory Committee Final Report. Washington, DC: US Environmental Protection Agency; 1998;
  80. Ma R, Cotton B, Lichtensteiger W, Schlumpf M. UV filters with antagonistic action at androgen receptors in the MDA-kb2 cell transcriptional-activational assay. Toxicological Sciences. 2003;74:43–50

PII: S1521-690X(05)00068-0

doi: 10.1016/j.beem.2005.09.001

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 1 , Pages 15-33 , March 2006

Article Tools

* Image Usage & Resolution